- Investing.com
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Metrics to compare | ANNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −7.1x | −0.5x | |
PEG Ratio | 0.14 | −0.12 | 0.00 | |
Price/Book | 4.5x | 6.5x | 2.6x | |
Price / LTM Sales | - | 198.3x | 3.2x | |
Upside (Analyst Target) | 87.1% | 252.5% | 47.4% | |
Fair Value Upside | Unlock | −16.4% | 7.7% | Unlock |